A thoughtful look into Switzerland’s cannabis pilot landscape — thanks to Der Bund and Martin Erdmann for shedding light on the Bern SCRIPT study.
What stands out: this is no longer an ideological debate.
It’s becoming a data-driven conversation.
Pilot studies like SCRIPT are critical because they test real-world questions:
- How does regulated access shape consumption behavior?
- What role can pharmacies play in harm reduction?
- How do pricing mechanisms impact the illicit market?
Early signals are already clear:
- Shift toward less harmful consumption methods
- Strong importance of quality, safety, and traceability
- Real tension between pricing and market realities
At Pure, we are proud to contribute to this effort.
As highlighted in the article, this is not a short-term business case.
It is a long-term investment into a functioning, responsible, and science-based cannabis market.
We would like to sincerely thank everyone involved in making this work possible: the teams at University of Bern and University of Lucerne, the participating pharmacies and healthcare professionals, the authorities and institutions supporting these pilot frameworks, and above all the study participants who contribute their time, trust, and lived experience. Their role is indispensable – also those whose work and contribution may not be visible in the article itself.
Switzerland is taking a pragmatic path:
test, learn, adapt — before scaling regulation.
That is how sustainable markets are built.
Read the full article (in German):HERE